Rising Osteoporosis in Women to drive Anti-Osteoporosis and Fracture Healing Market Growth

Anti-Osteoporosis and Fracture Healing Market

Anti-Osteoporosis and Fracture Healing Market by Drug Type (Bi-phosphates, Calcitonin, Estrogen or Hormone Replacement Therapy, Others), by Route of administration (Oral, Injectable, Others) and by DISTRIBUTION CHANNEL (Hospital Pharmacy, Drug Stores, Retail Pharmacy, E-commerce) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

The global Anti-Osteoporosis and Fracture Healing Market  is estimated to be valued at US$ 13.80 billion in 2023 and is expected to exhibit a CAGR of 8.51 % over the forecast period as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Several numerous fractures are complex by impaired curative. This is widespread in specific life-threatening groups such as geriatric, osteoporotic, and menopause women and in people suffering from malnutrition. Hence, there is an unfilled necessity for medications that can heal the bone. Parathyroid hormone anti-osteoporosis and fracture healing is the primary bone anabolic drug approved for the therapy of osteoporosis and enthrallingly several animal surveys prove the capability of anti –osteoporosis and fracture healing to persuade fracture healing. Anti-Osteoporosis and fracture healing might further be a potential new therapy chance in people with impaired recovery.

Competitive Landscape:

Key players involved in the growth of global Anti-Osteoporosis and Fracture Healing Market are F.Hoffmann La Roche Ltd., Eli Lilly and Company, Merck and Company Inc., Actavis plc, Novartis International AG., Teva Pharmaceutical Industries Ltd., Amgen Inc., Pfizer, Inc., and GlaxoSmithKline plc.

Market Key Drivers:

Rising prevalence of osteoporosis in women is expected to drive the growth of global Anti-Osteoporosis and Fracture Healing Market. For instance, as per IOF around 200 million women across the globe suffer from osteoporosis.

Rise of bone diseases due to the changing lifestyle is projected to propel the growth of global Anti-Osteoporosis and Fracture Healing Market. For instance, as per NIH over 1.5 million people across the globe suffer from bone disease.

Covid-19 Impact Analysis:

The Covid-19 outbreak had adversely affected the growth of the global Anti-Osteoporosis and Fracture Healing Market due to the surge in pandemic. The cases has led to the strict imposition of lockdown and restricted the visits to hospitals. The delay in visits to hospitals and shutdown of some clinics to curb the spread of virus is known to impede the market growth.

Key Takeaways:

The global Anti-Osteoporosis and Fracture Healing Market is expected to exhibit a CAGR of 8.51 % during the forecast period owing to the rising approvals, launches, mergers and acquisitions. For instance In September 2018, the U.S. FDA Administration approved the promotion of Risedronate Sodium Delayed release capsules in America. 

Among regions, North America, Asia Pacific and Europe anticipated to witness robust growth in the global Anti-Osteoporosis and Fracture Healing Market due to rising approvals and launches, rising geriatric population, increasing osteoporosis cases, rising R&D and increase investment on healthcare. For instance, as per NIH over 54% or 10 million people above the age of 50 years suffer from osteoporosis in U.S.